Drug Patents owned by Acorda

1. Drug name - INBRIJA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7384649 ACORDA Particulate compositions for pulmonary delivery Nov, 2022

(a month from now)

US9155699 ACORDA Pulmonary delivery for levodopa Mar, 2023

(5 months from now)

US8404276 ACORDA Pulmonary delivery for levodopa Mar, 2023

(5 months from now)

US8586093 ACORDA Pulmonary delivery for levodopa Mar, 2023

(5 months from now)

US7182961 ACORDA Particulate compositions for pulmonary delivery Feb, 2024

(1 year, 4 months from now)

USRE43711 ACORDA Pulmonary delivery for levodopa Feb, 2029

(6 years from now)

US8545878 ACORDA Capsules containing high doses of levodopa for pulmonary use Nov, 2032

(10 years from now)

US8685442 ACORDA Capsules containing high doses of levodopa for pulmonary use Nov, 2032

(10 years from now)

US8945612 ACORDA Capsules containing high doses of levodopa for pulmonary use Nov, 2032

(10 years from now)

US9393210 ACORDA Capsules containing high doses of levodopa for pulmonary use Nov, 2032

(10 years from now)

Drugs and Companies using LEVODOPA ingredient

Treatment: Intermittent treatment of off episodes in patients with parkinson's disease treated with carbidopa/levodopa by inhalation of levodopa powder particles

Dosage: POWDER;INHALATION

More Information on Dosage
Strength Dosage Availability
42MG POWDER;INHALATION Prescription

availability in other generic markets.

Click on the highlighted region to filter.